Show simple item record

dc.contributor.authorVasile, Francesca
dc.contributor.authorDella Volpe, Serena
dc.contributor.authorAmbrosio, Francesca Alessandra
dc.contributor.authorCosta, Giosuè
dc.contributor.authorUnver, M Yagiz
dc.contributor.authorZucal, Chiara
dc.contributor.authorRossi, Daniela
dc.contributor.authorMartino, Emanuela
dc.contributor.authorProvenzani, Alessandro
dc.contributor.authorHirsch, Anna K H
dc.contributor.authorAlcaro, Stefano
dc.contributor.authorPotenza, Donatella
dc.contributor.authorCollina, Simona
dc.date.accessioned2018-11-13T11:41:25Z
dc.date.available2018-11-13T11:41:25Z
dc.date.issued2018-09-13
dc.identifier.issn2045-2322
dc.identifier.pmid30214075
dc.identifier.doi10.1038/s41598-018-32084-z
dc.identifier.urihttp://hdl.handle.net/10033/621555
dc.description.abstractPost-transcriptional processes have been recognised as pivotal in the control of gene expression, and impairments in RNA processing are reported in several pathologies (i.e., cancer and neurodegeneration). Focusing on RNA-binding proteins (RBPs), the involvement of Embryonic Lethal Abnormal Vision (ELAV) or Hu proteins and their complexes with target mRNAs in the aetiology of various dysfunctions, has suggested the great potential of compounds able to interfere with the complex stability as an innovative pharmacological strategy for the treatment of numerous diseases. Here, we present a rational follow-up investigation of the interaction between ELAV isoform HuR and structurally-related compounds (i.e., flavonoids and coumarins), naturally decorated with different functional groups, by means of STD-NMR and Molecular Modelling. Our results represent the foundation for the development of potent and selective ligands able to interfere with ELAV-RNA complexes.en_US
dc.rightsAttribution-NonCommercial-ShareAlike 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/us/*
dc.titleExploration of ligand binding modes towards the identification of compounds targeting HuR: a combined STD-NMR and Molecular Modelling approach.en_US
dc.typeArticleen_US
dc.contributor.departmentHIPS, Helmholtz-Institut füt Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.en_US
refterms.dateFOA2018-11-13T11:41:25Z
dc.source.journaltitleScientific reports


Files in this item

Thumbnail
Name:
Vasile et al.pdf
Size:
2.137Mb
Format:
PDF
Description:
Open Access publication
Thumbnail
Name:
Vasile_supp.pdf
Size:
3.352Mb
Format:
PDF
Description:
supplementary materials

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 3.0 United States
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 3.0 United States